Abstract 15516: Three-Year Clinical Outcome of Patients Treated With the Nobori Biolimus-Eluting Stent and Xience/Promus Cobalt-Chromium Everolimus-Eluting Stent for Unprotected Left Main Disease
Introduction: The aim of this study was to evaluate 3-year clinical outcome of patients treated with the Nobori biolimus-eluting stent (BES) compared to those with the Xience/Promus cobalt-chromium everolimus-eluting stent (EES) for unprotected left main disease (ULMD).
Methods: Between February 2010 and July 2012, a total of 153 patients undergoing percutaneous coronary intervention for ULMD (63 BES and 90 EES) were analyzed. We assessed the rates of major adverse cardiac events (MACE), defined as a composite of cardiac death, non-fatal myocardial infarction (MI), definite stent thrombosis (ST), and clinically driven target lesion revascularization (TLR) within 3-year.
Results: Baseline patients and lesion characteristics were similar between BES and EES groups. No significant differences were observed with regard to lesion location (distal bifurcation lesion; 81.4% vs. 80.9%, p=0.93) and number of stent strategy (single stent strategy; 71.4% vs. 70.8%, p=0.93) between the 2 groups. The 3-year MACE rate was not significantly different between BES and EES groups (21.5% vs. 19.0%, p=0.83). The cumulative incidence of cardiac death, MI, ST, and clinically driven TLR rate were similar between the 2 groups (14.5% vs. 4.7%, p=0.07; 4.6% vs. 2.4%, p=0.45; 1.5% vs. 1.1%, p=0.86; 9.7% vs. 15.8%, p=0.30, respectively).
Conclusions: Three-year clinical outcome after BES implantation was not different from that after EES implantation for ULMD.
Author Disclosures: T. Hiromasa: None. S. Kuramitsu: None. H. Jinnouchi: None. T. Morinaga: None. Y. Kobayashi: None. T. Domei: None. M. Hyodo: None. Y. Soga: None. S. Shirai: None. K. Ando: None.
- © 2016 by American Heart Association, Inc.